https://www.diabetes.org.uk/about_us/news/trial-shows-type-1-diabetes-can-be-delayed  customer support advice people diabetes families coronavirus latest scientists shown new treatment slow immune attack causes type diabetes delaying point someone diagnosed condition findings first show diagnosis type diabetes delayed people median way calculating average two years results announced today american diabetes associations scientific sessions published new england journal medicine trial run trialnet international network scientists dedicated prevention type diabetes funded jdrf began involved people aged years yet type diabetes high risk developing condition future half volunteers received daily dose drug called teplizumab days half received dummy drug known placebo participants placebo group went develop type diabetes course study compared participants treated drug median time people placebo group develop clinical type diabetes months median time taking teplizumab months results suggest treatment able slow immune system destruction insulinproducing beta cells pancreas volunteers could keep making enough insulin longer delaying diagnosis type diabetes trialnet scientists previously discovered immune attack behind type diabetes different stages track stages someone reaches diagnosis condition gives us window opportunity disrupt immune attack progresses far way could protect beta cells order prevent least delay diagnosis type diabetes scientists use blood samples look signs immune attack underway suggesting someone high risk developing type diabetes future people high risk placed clinical trials like one testing teplizumab latest trial researchers tested drug teplizumab type immunotherapy scientists already studied teplizumab people recently diagnosed type diabetes found teplizumab could exhaust killer immune cells responsible attack became less effective attacking pancreas meant beta cells could survive longer latest study trialnet team wanted see could act even earlier development type diabetes majority someone beta cells still intact dr elizabeth robertson director research diabetes uk said today news trialnet incredibly exciting delighted see possible delay diagnosis type diabetes people research tackles root cause immune attack insulinproducing beta cells pancreas opens possibilities future research needed fully understand effects treatments like could benefit discovery drug could potentially provide people extra years free type diabetes harm causes significant moment important step towards future prevent condition entirely teplizumab appeared slow immune system attack stop entirely saw delay diagnosis rather complete prevention scientists plan follow volunteers treated templizumab develop type diabetes want look specific changes immune system learn drug works might effective others develop type diabetes scientists also want know treatment could provide benefits example could make blood glucose levels easier manage teplizumab type drug therapy called monoclonal antibody monoclonal means copies one type antibody made laboratory antibodies recognise bind specific molecules body case teplizumab recognises molecule found cells called cd find cells immune cells involved type diabetes immunotherapy spotlight page someone diagnosed diabetes every two minutes donation change lives british diabetic association operating diabetes uk charity registered england wales scotland sc company limited guarantee registered england wales registered office wells lawrence house back church lane london e fh 